

Sean D Sullivan Bscpharm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8642375/publications.pdf>

Version: 2024-02-01

109
papers

5,381
citations

126907

33
h-index

82547

72
g-index

109
all docs

109
docs citations

109
times ranked

6482
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness Analysis Alongside Clinical Trials – An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2015, 18, 161-172.	0.3	539
2	The Economic Burden of COPD. <i>Chest</i> , 2000, 117, 5S-9S.	0.8	507
3	The health economics of asthma and rhinitis. I. Assessing the economic impact. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 3-8.	2.9	490
4	Key principles for the improved conduct of health technology assessments for resource allocation decisions. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 244-258.	0.5	356
5	Trends in the cost of illness for asthma in the United States, 1985-1994. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 493-499.	2.9	328
6	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 277-283.	1.6	256
7	Cost Effectiveness of Lung-Volume Reduction Surgery for Patients with Severe Emphysema. <i>New England Journal of Medicine</i> , 2003, 348, 2092-2102.	27.0	218
8	The economic burden of asthma in US children: Estimates from the National Medical Expenditure Survey. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 957-963.	2.9	182
9	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic-Asthma Care. <i>JAMA Pediatrics</i> , 2004, 158, 875.	3.0	137
10	National Asthma Education and Prevention Program Working Group Report on the Cost Effectiveness of Asthma Care. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 154, S84-S95.	5.6	136
11	The cost-effectiveness of an inner-city asthma intervention for children. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 576-581.	2.9	129
12	Association of Early Imaging for Back Pain With Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1143.	7.4	104
13	Asthma outcomes: Healthcare utilization and costs. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, S49-S64.	2.9	88
14	A multifaceted hospitalist quality improvement intervention: Decreased frequency of common labs. <i>Journal of Hospital Medicine</i> , 2015, 10, 390-395.	1.4	75
15	Health Technology Assessment in Health-Care Decisions in the United States. <i>Value in Health</i> , 2009, 12, S39-S44.	0.3	73
16	Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 1229-1236.	2.9	69
17	AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management Organizations. <i>Journal of Managed Care Pharmacy</i> , 2001, 7, 272-282.	2.2	65
18	The Economic Costs of Asthma. <i>Pharmacoeconomics</i> , 1993, 4, 14-30.	3.3	63

#	ARTICLE	IF	CITATIONS
19	Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naïve Chronic Hepatitis C. <i>Pharmacoeconomics</i> , 2004, 22, 257-265.	3.3	63
20	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic Asthma Care. <i>JAMA Pediatrics</i> , 2005, 159, 428.	3.0	62
21	Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. <i>Value in Health</i> , 2019, 22, 661-668.	0.3	61
22	Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2148-2158.	4.4	59
23	Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery. <i>Pharmacoeconomics</i> , 2003, 21, 477-496.	3.3	58
24	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 71-78.	0.5	52
25	Level of asthma control and health care utilization in Asia-Pacific countries. <i>Respiratory Medicine</i> , 2014, 108, 271-277.	2.9	51
26	Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash. <i>American Journal of Public Health</i> , 2015, 105, e64-e69.	2.7	50
27	Updated Evaluation of the Cost-effectiveness of Lung Volume Reduction Surgery. <i>Chest</i> , 2007, 131, 823-832.	0.8	49
28	Design Issues for Conducting Cost-Effectiveness Analyses Alongside Clinical Trials. <i>Annual Review of Public Health</i> , 2001, 22, 129-141.	17.4	46
29	Resource costs for asthma-related care among pediatric patients in managed care. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 91, 251-257.	1.0	46
30	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536.	0.3	41
31	Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, 726-735.	2.2	40
32	Practice-Level Effects of Interventions to Improve Asthma Care in Primary Care Settings: The Pediatric Asthma Care Patient Outcomes Research Team. <i>Health Services Research</i> , 2005, 40, 1737-1757.	2.0	37
33	Modeling the Cost and Outcomes of Pharmacist-Prescribed Emergency Contraception. <i>American Journal of Public Health</i> , 2001, 91, 1443-1445.	2.7	35
34	Evidence, Economics, And Emphysema: Medicare's Long Journey With Lung Volume Reduction Surgery. <i>Health Affairs</i> , 2005, 24, 55-66.	5.2	33
35	A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism. <i>Pharmacoeconomics</i> , 2004, 22, 605-620.	3.3	29
36	Comparison of Directly Elicited Preferences to Preferences Derived from the SF-36 in Adults with Asthma. <i>Medical Decision Making</i> , 2003, 23, 323-334.	2.4	28

#	ARTICLE	IF	CITATIONS
37	Asthma in the United States: Recent Trends and Current Status. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 3-7.	2.2	28
38	Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis. <i>Value in Health</i> , 2015, 18, 173-179.	0.3	28
39	Economic Evaluation in the US. <i>Pharmacoeconomics</i> , 2006, 24, 1163-1168.	3.3	27
40	Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. <i>Journal of Medical Economics</i> , 2013, 16, 391-396.	2.1	26
41	Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. <i>BMC Medical Research Methodology</i> , 2019, 19, 119.	3.1	26
42	Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. <i>Journal of Medical Economics</i> , 2011, 14, 609-616.	2.1	25
43	Intention-to-Treat Analysis in Randomized Trials: Who Gets Counted?. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 667-672.	2.0	24
44	Health State Preference Assessment in Diabetic Peripheral Neuropathy. <i>Pharmacoeconomics</i> , 2002, 20, 1079-1089.	3.3	24
45	Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2123-2132.	4.4	24
46	Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1494-1499.	2.8	22
47	Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. <i>Cardiovascular Diabetology</i> , 2009, 8, 12.	6.8	21
48	Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery. <i>Value in Health</i> , 2006, 9, 68-76.	0.3	19
49	Role of Health Services Research in Producing High-Value Rehabilitation Care. <i>Physical Therapy</i> , 2015, 95, 1703-1711.	2.4	18
50	A Utility Assessment of Oral and Intravenous Ganciclovir for the Maintenance Treatment of AIDS-Related Cytomegalovirus Retinitis. <i>Pharmacoeconomics</i> , 1996, 10, 623-629.	3.3	17
51	The Promise of Specialty Pharmaceuticals: Are They Worth the Price?. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 3-6.	2.2	17
52	Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models. <i>Medical Decision Making</i> , 2019, 39, 294-298.	2.4	17
53	Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children with Asthma. <i>Journal of Asthma</i> , 2007, 44, 189-194.	1.7	15
54	Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 547-557.	2.1	15

#	ARTICLE	IF	CITATIONS
55	The Economics of Venous Thromboembolism Prophylaxis. Chest, 2003, 124, 393S-396S.	0.8	14
56	Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast, 2015, 24, 3-11.	2.2	14
57	Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. Journal of Oncology Practice, 2015, 11, e44-e49.	2.5	14
58	A Simulation of the Comparative Long-Term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus. Pharmacotherapy, 2009, 29, 1280-1288.	2.6	13
59	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. Journal of Comparative Effectiveness Research, 2017, 6, 461-470.	1.4	13
60	A Randomized Controlled Clinical Trial to Improve Asthma Care for Children Through Provider Education and Health Systems Change: A Description of the Pediatric Asthma Care Patient Outcome Research Team (PAC-PORT II) Study Design. Health Services and Outcomes Research Methodology, 2003, 4, 265-282.	1.8	12
61	A Forensic Evaluation of the National Emphysema Treatment Trial Using the Expected Value of Information Approach. Medical Care, 2008, 46, 542-548.	2.4	12
62	Price elasticities of pharmaceuticals in a value based formulary setting. Health Economics (United Kingdom), 2010, 30, 107-127.	1.7	12
63	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 2020, 36, 571-581.	1.9	12
64	A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. Diabetes, Obesity and Metabolism, 2020, 22, 2004-2012.	4.4	11
65	Development of a Quantifiable Symptom Assessment Tool for Patients with Chronic Bronchitis: The Chronic Bronchitis Symptoms Assessment Scale. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 209-216.	1.6	10
66	The Economic Burden of Chronic Obstructive Pulmonary Disease in the Asia-Pacific Region: A Systematic Review. Value in Health Regional Issues, 2019, 18, 121-131.	1.2	10
67	More Isn't Always Better: Cost-Effectiveness Analysis and the Case for Using a Split-Night Protocol. Journal of Clinical Sleep Medicine, 2006, 02, 155-154.	2.6	10
68	Managing Biotechnology In A Network-Model Health Plan: A U.S. Private Payer Perspective. Health Affairs, 2006, 25, 1347-1352.	5.2	9
69	Asthma Control and Cost in Latin America. Value in Health Regional Issues, 2014, 5, 25-28.	1.2	9
70	Pharmacists as health care providers: Lessons from California and Washington. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 39-44.	1.0	9
71	The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 981-986.	0.9	9
72	Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach. Journal of Comparative Effectiveness Research, 2012, 1, 241-255.	1.4	8

#	ARTICLE	IF	CITATIONS
73	An Economic Framework For Preventive Care Advice. Health Affairs, 2014, 33, 2034-2040.	5.2	8
74	Toward a Hedonic Value Framework in Health Care. Value in Health, 2017, 20, 261-265.	0.3	8
75	Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. Obesity Surgery, 2018, 28, 1321-1328.	2.1	8
76	Integrating Formal Technology Assessment into an Integrated Healthcare Delivery System: Smart Innovation. International Journal of Technology Assessment in Health Care, 2020, 36, 58-63.	0.5	8
77	Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 223-239.	0.9	8
78	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 277-283.	1.6	8
79	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. Applied Health Economics and Health Policy, 2019, 17, 733-740.	2.1	7
80	Quality of clinical and economic evidence in dossier formulary submissions. American Journal of Managed Care, 2007, 13, 401-7.	1.1	7
81	Rapporto costo-efficacia della terapia peginterferone Î±-2a + ribavirina in confronto a interferone Î±-2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. Pharmacoeconomics Italian Research Articles, 2004, 6, 105-114.	0.2	6
82	Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 689-695.	0.9	6
83	Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports. Value in Health, 2021, 24, 789-794.	0.3	6
84	Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinsonâ€™s disease patients treated with levodopa/carbidopa. Journal of Medical Economics, 2021, 24, 563-569.	2.1	5
85	Insulin glargine 300â€‰%units/<sc>mL</sc> for the treatment of individuals with type 2 diabetes in the real world: A review of the <sc>DELIVER</sc> programme. Diabetes, Obesity and Metabolism, 2021, 23, 1713-1721.	4.4	5
86	Clinical outcomes in highâ€‰hypoglycaemiaâ€‰risk patients with type 2 diabetes switching to insulin glargine 300â€‰U/mL versus a firstâ€‰generation basal insulin analogue in the United States : Results from the DELIVER High Risk realâ€‰world study. Endocrinology, Diabetes and Metabolism, 2022, 5, e00306.	2.4	5
87	Emerging Therapeutic Strategies for Asthma Management. Journal of Managed Care Pharmacy, 2003, 9, 14-21.	2.2	4
88	Comparative effectiveness research in the United States: a progress report. Journal of Medical Economics, 2013, 16, 295-297.	2.1	4
89	Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. International Journal of Breast Cancer, 2016, 2016, 1-10.	1.2	4
90	Home care reimbursement for intravenous ganciclovir therapy. American Journal of Health-System Pharmacy, 1996, 53, 161-163.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Introduction. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 2-2.	2.2	3
92	133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk). <i>Diabetes</i> , 2019, 68, 133-LB.	0.6	3
93	Evaluating HTA principles. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 429-430.	0.5	2
94	Returns to scientific publications for pharmaceutical products in the United States. <i>Health Economics (United Kingdom)</i> , 2018, 27, 282-293.	1.7	2
95	Application of Health Technology Assessment (HTA) to Evaluate New Laboratory Tests in a Health System: A Case Study of Bladder Cancer Testing. <i>Academic Pathology</i> , 2020, 7, 237428952096822.	1.1	2
96	<i>Health Economics</i> . , 2002, , 657-671.		2
97	Consensus guidelines for specialty pharmaceuticals: a best-practice approach for cost-effective management. <i>American Journal of Managed Care</i> , 2004, 10, S242-4; discussion 245-51.	1.1	2
98	Assessing the early impact of a hospital-based health technology assessment program, smart innovation. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, .	0.5	1
99	The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-40.	1.6	1
100	Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 570-570.	1.6	1
101	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. <i>BMC Health Services Research</i> , 2022, 22, 432.	2.2	1
102	A pragmatic cluster-randomized trial of a standing physician order entry intervention for colony stimulating factor use among patients at intermediate risk for febrile neutropenia (SWOG S1415CD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1518-1518.	1.6	1
103	A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for patients with cancer receiving myelosuppressive chemotherapy (SWOG S1415CD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1525-1525.	1.6	1
104	US health care reform: a work in progress. <i>European Journal of Health Economics</i> , 2010, 11, 117-118.	2.8	0
105	Evolution of the AMCP Format for Formulary Submissions. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 696-700.	0.9	0
106	The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 41-41.	1.6	0
107	The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-9.	0.9	0
108	International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 566-572.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Overall survival (OS) of patients with TRK fusion ⁺ positive cancer receiving larotrectinib versus standard of care (SoC): A matching-adjusted indirect comparison (MAIC) using real-world data (RWD).. Journal of Clinical Oncology, 2022, 40, 6579-6579.	1.6	0